

Original Research Article

Seroepidemiology of toxoplasmosis in pregnant women attending antenatal clinics at the centre for maternal and child health care in Daloa in Ivory Coast.

ABSTRACT

Background: Serological tests remain the basis of toxoplasmosis diagnosis since direct detection of *Toxoplasma gondii* by microscopy is less sensitive and PCR is inaccessible for routine screening. Unfortunately, serological screening in pregnant women for *T. gondii*-specific antibodies is not mandatory in the assessment of antenatal care in Ivory Coast. Furthermore the latest data published are about a decade.

Aim: To determine the seroprevalence in relation with certain risk factors and discuss epidemiological issue of different patterns seen among pregnant women in Daloa, in Ivory Coast.

Study design and setting: This is a prospective study. Pregnant women attending antenatal care clinics in maternal and child health care centre were screened for IgG and IgM antibodies against *T. gondii* from February to August 2014.

Results:

Of the 385 women, 113 (29.35%) were in their first pregnancy and the average age was 26 years with 14 and 47 years of age respectively the youngest and the oldest mother. (42.85%) of the women have already been in contact with cat and 305 (79.22%) eaten crude vegetable. 118 (28.05%) out of 385 women were in the third trimester of pregnancy.

226 out of 385 sera (58.70%) had positive IgG and all sera were tested negative for IgM. The remaining sera 159 (41.3%) had no IgG or IgM. The seroprevalence of IgG was correlated to the presence of cat in the household ($P=0.001$) and age group ($P<0.05$), whereas no significant association was observed with the consumption of raw vegetables, education and the type of housing. Of the 159 sera tested negative, 45 (28.3%) were collected in third trimester of pregnancy.

Conclusion: Our study shows that the prevalence of toxoplasmosis among women of reproductive age, particularly pregnant women is not insignificant in Ivory Coast and deserves more attention from the health officials.

Keywords: *Toxoplasmosis, seroprevalence, epidemiology, Daloa, Ivory Coast.*

1. INTRODUCTION

Toxoplasmosis is among the global major zoonotic diseases [1, 2]. It is the third leading infectious cause of food-borne and waterborne death after salmonellosis and listeriosis [3] and affect about one third of the humanity [4]. The disease is caused by *Toxoplasma gondii*, an Apicomplexa protozoan parasite [5], with cats as the definitive host, and warm-blooded animal as intermediate hosts [6]. Humans can become infected by contact with infected animals, eating raw food contaminated with oocysts, such as vegetables and fruits but also by water and meat containing encysted bradyzoites [7]. The seroprevalence of toxoplasmosis vary substantially depending on sanitation level of the population, dietary habits, contact with cats, contact with contaminated soil [8, 9], *T. gondii* virulence [10] and varies between geographic areas [11].

The majority of infections are asymptomatic in immunocompetent individuals, possibly because the organism has co-evolved with its many vertebrate hosts and has developed multiple strategies to persist asymptotically for the lifetime of the host [12]. Its severity lies in cases where the parasite invades immunocompromised subjects [7] and pregnant women.

In this latter case, it may cause a serious type of foetopathy hypotonia, microcephaly, chorioretinitis [13]. In women, primary infection with *T. gondii* during the third trimester of pregnancy carries a higher risk of congenital transmission than if it is acquired during the first trimester [14,15]. Antenatal serological screening of *T. gondii* infection based on IgG and IgM detection is the mainstay in monitoring the risk for congenital toxoplasmosis [16]. The direct demonstration of parasites (microscopy, mouse inoculation, cell culture, PCR) is tricky and inaccessible in the context of routine screening [17,18].

Besides the major African endemic diseases such as malaria, trypanosomiasis and schistosomiasis, toxoplasmosis may seem secondary, even if it affects 14-92.5% of patients across countries [19,20,21]. Indeed, if pregnant women in developed countries benefit from a special monitoring where *Toxoplasma gondii* serology is one of the examinations required in early pregnancy [22], this test is not mandatory in the assessment of pregnancy in many African countries [23,24]. The lack of public health schemes to manage the spread of this pathogen places African women populations at risk of ongoing and possibly increasing incidence and prevalence, as well as a corresponding increase in mortality and morbidity due to toxoplasmosis. In Ivory Coast, there is no screening program during antenatal care for pregnant women and the most recent study available in the literature dates back about ten years [23] although the incidence on pregnancies and newborns is not insignificant. Therefore this study aims to determine the serological status in a population of pregnant women from the city of Daloa in the Centre-West of Ivory Coast, to draw the appropriate epidemiological consequences.

2. MATERIALS AND METHODS

2.1 Study Design

This is a prospective study carried out at the maternal and child health care centre in Daloa among patients attending antenatal care who give their consent, from February to August 2014. ~~In this hospital, as elsewhere in Ivory Coast, the diagnosis of toxoplasmosis does not fit into the antenatal record. There is no program or screening or systematic monitoring of toxoplasmosis in pregnant women.~~

2.2 Study Population and Serological diagnosis

Random sampling was used in selecting pregnant women attending antenatal clinics without notion of prior serological results. They were asked for consent and those who consented were interviewed and sera were collected and stored at -20°C prior to Enzyme Linked Fluorescent Assay (ELFA) test. The lab technician routinely informed a questionnaire including socio-demographic factors such as age, type of housing, presence of cats, consumption of raw fruit and vegetables, trimester of pregnancy and number of pregnancy.

The sample size was determined according the formula $N = Z^2 \cdot P \cdot (1-P) / E$ [25].

N=minimum sample size required for the study; Z=the standard normal deviation, usually 1.96 at 95% confidence level; P=prevalence rate 60% prevalence of toxoplasmosis in women [23]. E= precision rate (5%), degree of accuracy. Therefore N=368 parturient women (but 385 were used).

Toxoplasmosis IgG titre was conducted by ELFA technique on a controller Vidas^R (BioMérieux^R) (Kit VidasToxo IgG II) (BioMérieux^R). Results are expressed in International Units per mL (IU / mL). Serology with an IgG titre greater than 8 IU / mL was considered positive. The Toxo ISAGA test (BioMérieux^R) **allowed** the specific detection of anti-toxoplasma IgM by immunocapture technique.

2.3 Data Analysis

Sociodemographic data related with serology results were registered in an excel database and analyzed by a chi-square statistical test using STATA ($\alpha < 5\%$) [26].

79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

2.4 Ethical Issues

This study was approved by the Research National Ethics Committee before implementation. All participants provided written informed consent. The tests were conducted free of charge for women wishing to participate in the study.

3. RESULTS

3.1 Sociodemographic data

In this prospective study, 385 sera were collected from pregnant women attending the maternal and child health care centre. Of the 385 women, 113 (29.35%) were in their first pregnancy and the average age was 26 years with 14 and 47 years of age respectively the youngest and the oldest mother. 165 (42.85%) of the women have already been in contact with cat and 305 (79.22%) eaten crude vegetable. 108 (28.05%) out of 385 women were in the third trimester of pregnancy (Table 1).



3.2 Serological data

On the 385 sera tested, 226 (58.70%) had positive IgG and all sera were tested negative for IgM. The remaining sera 159 (41.3%) had no IgG or IgM. The seroprevalence of IgG was correlated to the presence of cat in the household ($P < 0.001$) and age group ($P < 0.05$), whereas no significant association was observed with the consumption of raw vegetables, education and the type of housing. Of the 159 five sera tested negative, 45 (28.3%) were collected in third trimester of pregnancy (Table 1).

103

Table 1. Distribution of *Toxoplasma gondii* seroprevalence along with Sociodemographic characteristics

Demographic characteristics	IgG seroprevalence		X ²	p-value
	Number examined	Number of positive (%)		
Age group (Year)				
14-23	158	89(56.32)	7.04	0.02
24-33	190	108(56.84)		
34-43	37	29(78.37)		
Type of housing				
Common home	215	130(60.46)	1.41	0.49
Individual housing	170	96(56.47)		
Education				
Illiterate	176	109(61.93)	2.44	0.48
Primary	115	61(53.04)		
Secondary	76	46(60.52)		
University	18	10(55.56)		
Gravidity				
Primigravid	113	63(55.75)	0.89	0.63
Multigravid	143	88(61.53)		
Grandmultipare	129	75(58.13)		
Cat				
No	220	108(49.09)	19.9	0.0001
Yes	165	118(71.51)		
Consumption of raw vegetable				
No	80	47(58.75)	0.001	0.99
Yes	305	179(58.68)		
Trimester of pregnancy				
First Trimester	136	77(56.61)	0.72	0.69
Second Trimester	141	86(60.99)		
Third trimester	108	63(58.33)		

104

105

106 DISCUSSION

107 This study was conducted, at the centre for maternal and child health care, in Daloa city, in
 108 Ivory Coast, among pregnant women without a notion of prior serological results. The aim of

our study was to determine the initial serological status of parturient women and to derive action to be taken. The overall seroprevalence of toxoplasmosis in our population (58.7%) is statistically consistent with that reported on women of reproductive age in previous study in Abidjan, the economic capital of Ivory Coast [23] and may be stable on a decade from south to west of the country.

When comparing the toxoplasmosis seroprevalence of our study to those found in west-African countries where literature does exist for at least the latest decade (2004-2013), it appears that toxoplasmosis seroprevalence is very higher in Ghana and low in Nigeria, Burkina Faso and Benin (Table 2).

Table 2. *Toxoplasma gondii* seroprevalence in West African women from 2004 to 2014

Year	Country	Sample size	Prevalence (%)	References
2004	Ivory coast	1025	60.00	Adou-Bryn et al[23]
2006	Burkina Faso	336	25.30	Simpore et al[27]
2009	Ghana	159	92.50	Ayi et al, [19]
2011	Nigeria	276	32.60	Deji-Agboola et al[28]
2011	Senegal	941	34.50	N'Diaye et al[29]
2012	Burkina Faso	306	31.00	Bamba et al[30]
2013	Nigeria	173	27.75	Alayande et al[31]
2014	Benin	283	30.00	De Paschale et al[32]

This variability between countries of the same region may have climate causes. Indeed, Adoubryn et al[23] had already noted that humid countries have higher seroprevalence than Sahelian ones. In a study conducted in Ghana in 2009, the 159 women aged 15-40 randomly investigated showed an overall seroprevalence of 92.5% [19]. This is the highest prevalence reported in West Africa till now. In Benin, the seroprevalence of 30% observed in 2014 by De Paschale et al[32] is very different from that observed there about two decades before by Rodier et al[33] which was 53.6%. Recent studies conducted in Nigeria by Deji-Agboola et al[28] in 2011 and Alayande et al[31] in 2013 give 32.6% and 27.75% as prevalence respectively that are statistically identical ($P < 0.05$) but very different from what was reported two decades ago by Onadeko et al, [34], which was 75.4%. This difference could be due to variations in geographic patterns within the same country. Indeed, Nigeria is a vast country with a large area covering wet and dry regions as well. The same observation is made in Senegal, where a recent study showed a prevalence of 34.5% [29] whereas 10 years before, the prevalence was around 60% [35]. Regarding in Burkina Faso, the prevalence is stable according to Simporé et al[27] in 2006 and Bamba et al[30] who reported the respective prevalence of 25.3% and 31%, confirming that the lowest prevalence of toxoplasmosis are mostly recorded in dry regions [23,36].

In this study, it should be noted that none of the sera tested had positive IgM. This pattern is slightly different from the one previously published by Adoubryn et al[23] where 0.4% of IgG were associated with the presence of IgM in the southern Ivory Coast. The presence of IgG and absence of IgM (IgG⁺ and IgM⁻) in our study population for a first toxoplasma serology without any prior information in pregnant women, advocates a former probable immunity. In this context, 58.7% of women are not likely to transmit the infection to their children without any immunosuppression. Then, they would not require additional supervision during

pregnancy if a toxoplasmosis monitoring program was introduced [37]. However, in such case, we recommended a second serological test three weeks after the first serodiagnosis, to monitor changes in IgG level. Thus, a stable titre would definitely conclude to past infection while an increase in antibody titre after these three weeks should lead physicians to a more precise dating of the infection with the help of additional serological techniques to assess the risk to the fetus.

In case of known immunosuppression, the presence of IgG and absence of IgM even if it evokes an old probable infection, may require serological surveillance and must be interpreted in light of the clinical and the degree of immunosuppression. Only the subsequent analysis of two sera at intervals of about three weeks in the same laboratory by the same technique allows a definitive conclusion [19]. Hence the need to counsel women to make a second examination.

41.3% of the women in this study do not present toxoplasmosis-specific IgG or IgM. This demonstrates a lack of toxoplasma immunity with a risk of gestational seroconversion [37,38]. These women must be monitored regularly to detect any seroconversion (appearance of IgM and IgG). In case of confirmed seroconversion, the fetus is at risk of congenital infection, risks that varies depending on the gestational age at the time of maternal contamination. Parturient affected should get into a rigorous monitoring program (ultrasound and/or parasitological follow-up). It is noteworthy that in cases of antenatal seroconversion with evolution of serum signature and occurrence of clinical signs such as lymphadenopathy, fetal transmission may be probable [37,38]. In this study, the proportion of parturient that is still at risk of seroconversion during late pregnancy because not immunized (41.3%) is substantial. In order to reduce the risk of transmission of congenital toxoplasmosis in 159 non-immune women of our study, two preventive attitudes may be recommended: Firstly, regular control of serology if possible monthly until delivery and even nearest postpartum and secondly, application of hygienic dietary recommendations.

175

176 4. CONCLUSION

~~The first objective of toxoplasma serology tests in women in early pregnancy is to identify non-immune pregnant women so that they benefit from prevention advice (wash hands, consume very cooked meat, avoid contact with cats and other felines) to avoid contamination during pregnancy.~~ Our data show that 41.3% of pregnant women are likely to become infected during pregnancy because of their lack of anti-toxoplasma immunity with the risk of congenital toxoplasmosis for their fetus. Further to the seroepidemiology, our study is in line with the Millennium Development Goals (MDGs) 4 and 5 which aim to reduce substantially the under five mortality rate and improve maternal health by 2015 and shows the need to establish a serological surveillance program as soon as possible during pregnancy as a first step to prevention of congenital toxoplasmosis. This should be combined with clear information within unimmunized pregnant women vis-à-vis toxoplasmosis offering prophylactic recommendations (lifestyle and dietary rules, hygiene, avoid contact with cats and gardening activities).

190

191

192 REFERENCES

- 193 1. Petersen E, Vesco G, Villari S, Buffolano W. What do we know about risk factors for
194 infection in humans with *Toxoplasma gondii* and how can we prevent infections? *Zoonoses*
195 *Public Health*. 2010, 57:8–17.
- 196 2. Torgerson PR, Macpherson CNL. The socioeconomic burden of parasitic zoonoses:
197 Global trends. *Vet Parasitol*. 2011, 182:79–95.
- 198 3. Dubey JP. Toxoplasmosis: a waterborne zoonosis. *Vet Parasitol*. . 2004, 126:57–72.
- 199 4. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of *Toxoplasma gondii*
200 in man and animals. *Anim Health Res Rev*. 2005, 6:41–61.

- 201 5. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans.
202 *Int J Parasitol.* 2000, 30:1217–1258.
- 203 6. Dubey JP. *Toxoplasmosis of animals and humans*. 2nd edition. Beltsville, Maryland:
204 U.S.A. CRC Press, 2010.
- 205 7. Cenci-Goga BT, Rossitto PV, Sechi P, McCrindle CM, Cullor JS . *Toxoplasma* in
206 animals, food, and humans: an old parasite of new concern. *Foodborne Pathog Dis.* 2011,
207 8:751–762.
- 208 8. Avelino MM, Campos DJ, Parada JB, Castro AM. Risk factors for *Toxoplasma gondii*
209 infection in women of childbearing age. *BJID.* 2004, 8(2):164–174.
- 210 9. Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. *Toxoplasmosis in humans and*
211 *animals in Brazil: high prevalence, high burden of disease, and epidemiology.* *Parasitology.*
212 2012,139(11):1375–1424).
- 213 10. Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LMG, Tan HK, Wallon M, Buffolano
214 W, Stanford MR, Petersen E. Ocular sequelae of congenital toxoplasmosis in Brazil
215 compared with Europe. 2008, *PLoS Negl Trop Dis*, 2: 277.
- 216 11. Di Carlo P, Romano A, Schimmenti MG, Mazzola A, Titone L. Materno- fetal
217 *Toxoplasma gondii* infection. Critical review of available diagnostic methods. *Infez Med*
218 2008, 16(1):28–32).
- 219 12. Hunter CA, Sibley LD. Modulation of innate immunity by *Toxoplasma gondii*
220 virulence effectors. *Nature Reviews Microbiology.* 2012, 10:766-778.
- 221 13. Costache CA, Colosi HA, Blaga L , Györke A, Pastiu AI, Colosi IA, Ajzenberg D.
222 .First isolation and genetic characterization of a *Toxoplasma gondii* strain from a
223 symptomatic human case of congenital toxoplasmosis in Romania. *Parasite.* 2013, 20, 11.
- 224 14. Al-Hamdani M, Mahdi N. Toxoplasmosis among women with habitual abortion.
225 *EMHJ.* 1997, 3:310–315.
- 226 15. Dunn DWM, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child
227 transmission of toxoplasmosis: risk estimates for clinical counseling. *Lancet.* 1999,
228 353:1829–1833.
- 229 16. Petithory JC, Ambroise-Thomas P, De Loyer J, Pelloux H, Goullier-Fleuret A,
230 Milgram M, Buffard C, Garin JP. Serodiagnosis of toxoplasmosis : a comparative multicenter
231 study of a standard scale through various actual tests and expression of the results in
232 international units. *Bull WHO.* 1996, 74:291-298.
- 233 17. Fricker-Hidalgo H, Pelloux H, Racinet C, Grefenstette I, Bost-Bru C, Goullier-Fleuret
234 A, Ambroise-Thomas P. Detection of *Toxoplasma gondii* in 94 placentae from infected
235 women by polymerase chain reaction, in vivo, and in vitro cultures. *Placenta.* 1998, 19:545-
236 549.
- 237 18. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. Prenatal diagnosis
238 using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. *Obstet*
239 *Gynecol.* 2001, 97:296-300.
- 240 19. Ayi I, Edu SA, Apea-Kubi KA, Boamah D, Bosompem KM, Edoh D. Sero-
241 epidemiology of toxoplasmosis amongst pregnant women in the greater accra region of
242 Ghana. *Ghana Med J.* 2009, 43(3):107-114.
- 243 20. Monjour L, Niel G, Palminteri R, Sidatt M, Daniel-Ribeiro C, Alfred C, Gentilini M. An
244 epidemiological survey of toxoplasmosis in Mauritania. *Trop Geog Med.* 1983, 35:21-24.
- 245 21. Ritter J, Doucet J, Pothier MA, Duchassin M, Diarras S. La toxoplasmosé chez la
246 femme enceinte. *Ann Univ Abidjan.* 1972, 6:157-165. French
- 247 22. Lopes-Mori FMR, Mitsuka-Bregano R, Capobiango JD, Inoue IT, Reische EMV,
248 Morimoto HK, Casella AMB, Bittencourt LHFDB, Freire RL, Navarro IT. Programs for control
249 of congenital toxoplasmosis. *Rev. Assoc. Med. Bras.* 2011, 57(5):581-586.
- 250 23. Adou-Bryn KD, Ouhon J, Nemer J, Yapo CG, Assoumou A. Enquête sérologique de
251 la toxoplasmosé acquise chez les femmes en âge de procréer à Yopougon (Abidjan, Côte
252 d'Ivoire). *Bull Soc Pathol Exot.* . 2004, 97(5):345-348.Fench

- 253 24. Hammond-Aryee K, Esser M, Van Helden PD. *Toxoplasma gondii* seroprevalence
254 studies on humans and animals in Africa. S Afr Fam Pract. . 2014, 56(2):119-12.
- 255 25. Arroyo MO. Subject selection. Research methodology with statistics for health and
256 social sci. Natadox publishers, Ilorin Nigeria. 2003; 115-129.
- 257 26. StataCorp. *Stata Statistical Software: Release 9*. College Station, TX: StataCorp LP.
258 2005.
- 259 27. Simpoire J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, Pignatelli
260 S, Pietra V, Musumeci S. 2006. *Toxoplasma gondii*, HCV, and HBV seroprevalence and co-
261 infection among HIV positive and negative pregnant women in Burkina Faso. J Med Virol.,
262 78(6):730- 3.
- 263 28. Deji-Agboola AM, Busari OS, Osinupebi OA, Amoo AOJ. Seroprevalence of
264 *Toxoplasma gondii* antibodies amongst pregnant women attending Antenatal Clinic of
265 Federal Medical Center, Lagos, Nigeria. International Journal of Biological and Medical
266 Science. 2011, 2(4):1135-1139.
- 267 29. Ndiaye D, Sène PD, Ndiaye M, Faye B, Ndiaye JL, Ndir O. Evolution de la
268 séroprévalence de la toxoplasmose chez la femme enceinte à Dakar, Sénégal de 2002 à
269 2006. Med.Trop. 2011, 71(1):101-2. French
- 270 30. Bamba S, Some A, Chemla C, Geers R, Guiguemde TR, Villena. Analyse
271 sérologique de la toxoplasmose pergravidique: évaluation des risques et perspectives du
272 dépistage prénatal au centre hospitalier universitaire de Bobo Dioulasso au Burkina Faso.
273 Pan African Medical Journal. 2012, 1937-8688. French
- 274 31. Alayande MO, Edungbola ID, Fabiyi JP, Faleke OO., Babatunde SK, Akanbi AA,
275 and Nyamngee I. *Toxoplasma gondii* and intestinal helminthes infection among owned
276 strayed cat in Sokoto, Nigeria. Res. J. Vet. Sci. 2012, 5(3):69-74.
- 277 32. De Paschale M, Ceriani C, Cerulli T, Cagnin D, Cavallari S, Cianflone A, Diombo K,
278 Ndayaké J, Aouanou G, Zaongo D, Priuli G, Viganò P, Clerici P. Antenatal screening for
279 *Toxoplasma gondii*, Cytomegalovirus, rubella and *Treponema pallidum* infections in northern
280 Benin. Tropical Medicine & International Health. 2014, 19(6): 743–746.
- 281 33. Rodier MH, Berthonneau J, Bourgoïn A, Giraudeau G, Agius G, Burucoa.
282 Seroprevalences of *Toxoplasma*, malaria, rubella, cytomegalovirus, HIV and treponemal
283 infections among pregnant women in Cotonou, Republic of Benin. Acta Trop. 1995,
284 59(4):271-277.
- 285 34. Onadeko MO, Joynton D H, Payne RA, Francis J. The prevalence of toxoplasma
286 antibodies in pregnant Nigerian women and the occurrence of stillbirth and congenital
287 malformation. Afr J Med Med Sci. 1996, 25:331-334.
- 288 35. Pangui LJ, Gbati OB, Kamga WAR, Bakou SN. Point sur la toxoplasmose en Afrique
289 de l'ouest et du centre. RASPA. . 2014, 11 N°S. French
- 290 36. Jones JL, Holland GN. Annual burden of ocular toxoplasmosis in the US. Am JTrop
291 Med Hyg. 2010, 82:464–465.
- 292 37. Montoya JG, Remington JS. Management of *Toxoplasma gondii* Infection during
293 Pregnancy. Clin Infect Dis. 2008, 47(4):554-66.
- 294 38. King L, Villena I, Ancelle T, Wallon M, Garcia P, Thulliez P. Toxoplasmose
295 congénitale: Mise en place d'un système de surveillance en France. Bull Epidemiol Hebdom.
296 2008, 14-15:122-24. French